Locations:
SearchHeart team approach essential for individual patient decisions
Recent results from the SURTAVI trial add to mounting evidence that transcatheter aortic valve replacement (TAVR) can fully match surgical aortic valve replacement for safety and efficacy in appropriately selected patients at intermediate surgical risk. In the one-minute video below, Cleveland Clinic interventional cardiologist Amar Krishnaswamy, MD, puts the SURTAVI findings in context and offers perspective on the heart team approach that’s needed to help patients make the best choice between these two good treatment options.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
For a more detailed (eight-minute) video by Dr. Krishnaswamy on TAVR’s role in intermediate-risk patients, see the video here.
Advertisement
Advertisement
A sampling of outcome and volume data from our Heart & Vascular Institute
Concomitant AF ablation and LAA occlusion strongly endorsed during elective heart surgery
Large retrospective study supports its addition to BAV repair toolbox at expert centers
Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy
Surprise findings argue for caution about testosterone use in men at risk for fracture
Residual AR related to severe preoperative AR increases risk of progression, need for reoperation
Findings support emphasis on markers of frailty related to, but not dependent on, age
Provides option for patients previously deemed anatomically unsuitable